Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study
- jeanfrancoismaison
- May 2
- 1 min read
top of page
Search
Recent Posts
See Allhttps://pubmed.ncbi.nlm.nih.gov/40467521/
https://pubmed.ncbi.nlm.nih.gov/40450523/
https://pubmed.ncbi.nlm.nih.gov/40464483/
bottom of page
Comments